Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer

Anticancer Research

Volumn 30, Issue 5, 2010, Pages 1807-1813

  Rack, Brigitte ^a   Jückstock, Julia ^a   Genss, Eva Maria ^a   Schoberth, Alexandra ^b   Schindlbeck, Christian ^a   Strobl, Barbara ^a   Heinrigs, Maja ^a   Rammel, Gerhard ^a   Zwingers, Thomas ^c   Sommer, Harald ^a   Friese, Klaus ^a   Janni, Wolfgang ^d  

^a UNIVERSITY OF MUNICH   (Germany)

^b Laboratory Drs Tiller and Partners   (Germany)

^c Fa Estimate GmbH Augsburg   (Germany)

^d UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Breast cancer; Isolated tumour cells; Minimal residual disease; Recurrence free follow up; Zoledronate treatment

Indexed keywords

CYTOSTATIC AGENT; GONADORELIN DERIVATIVE; LETROZOLE; TAMOXIFEN; TRASTUZUMAB; ZOLEDRONIC ACID;

ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BODY TEMPERATURE; BONE MARROW BIOPSY; BONE METASTASIS; BONE PAIN; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DYSPNEA; EARLY CANCER; EDEMA; FOLLOW UP; HUMAN; HUMAN TISSUE; LOADING DRUG DOSE; PHASE 1 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; SIDE EFFECT; TUMOR CELL; VISCERAL METASTASIS; VOMITING;

ADULT; AGED; BONE DENSITY CONSERVATION AGENTS; BONE MARROW; BONE MARROW CELLS; BREAST NEOPLASMS; CELL CYCLE; CHEMOTHERAPY, ADJUVANT; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMIDAZOLES; MIDDLE AGED; MODELS, STATISTICAL; RECURRENCE;

EID: 77954572691     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Janni W, Wiedswang G, Fehm T, Jückstock J, Borgen E, Rack B, Braun S, Sommer H, Solomayer EF, Pantel K, Nesland JM, Friese K and Naume B: Persistence of disseminated tumor cells (DTC) in bone marrow (BM) during follow-up predicts increased risk for relapse - Update of the pooled European data. SABCS, 2006.
2. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A and Pantel K: A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353: 793-802, 2005. (Pubitemid 41215488)
3. Pantel K, Cote RJ and Fodstad O: Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 91: 1113-1124, 1999. (Pubitemid 29330549)
4. Klein CA, Schmidt-Kittler O, Schardt JA, Pantel K, Speicher MR and Riethmuller G: Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc Natl Acad Sci USA 96: 4494-4499, 1999.
5. Braun S, Kentenich C, Janni W, Hepp F, de Waal J, Willgeroth F, Sommer H and Pantel K: Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 18: 80-86, 2000. (Pubitemid 30036339)
6. Verdijk R, Franke HR, Wolbers F and Vermes I: Differential effects of bisphosphonates on breast cancer cell lines. Cancer Lett 246: 308-312, 2007.
7. Fromigue O, Lagneaux L and Body JJ: Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 15: 2211-2221, 2000.
8. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M and Bastert G: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339: 357-363, 1998.
9. Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S, Pajunen M, Nevantaus A, Mannisto E, Suovuori A, Atula S, Nevalainen J and Pylkkanen L: Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20: 3219-3224, 2002.
10. Pantel K, Felber E and Schlimok G: Detection and characterization of residual disease in breast cancer. J Hematother 5: 315-322, 1994.
11. Janni W, Hepp F, Rjosk D, Kentenich C, Strobl B, Schindlbeck C, Hantschmann P, Sommer H, Pantel K and Braun S: The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence. Cancer 92: 46-53, 2001. (Pubitemid 32623039)
12. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmuller G and Schlimok G: Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342: 525-533, 2000. (Pubitemid 30117892)
13. Stigbrand T, Andres C, Bellanger L, Bishr OM, Bodenmuller H, Bonfrer H, Brundell J, Einarsson R, Erlandsson A, Johansson A, Leca JF, Levi M, Meier T, Nap M, Nustad K, Seguin P, Sjodin A, Sundstrom B, van Dalen A, Wiebelhaus E, Wiklund B, Arlestig L and Hilgers J: Epitope specificity of 30 monoclonal antibodies against cytokeratin antigens: the ISOBM TD5-1 Workshop. Tumour Biol 19: 132-152, 1998.
14. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KA, Stein H and Mason DY: Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 32: 219-229, 1984.
15. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
16. Cox DR: Regression models and life tables. J R Stat Soc B 34: 187-220, 1972.
17. Janni W, Rack B, Schindlbeck C, Strobl B, Rjosk D, Braun S, Sommer H, Pantel K, Gerber B and Friese K: The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer 103: 884-891, 2005. (Pubitemid 40270064)
18. Wiedswang G, Borgen E, Karesen R, Qvist H, Janbu J, Kvalheim G, Nesland JM and Naume B: Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clin Cancer Res 10: 5342-5348, 2004.
19. Fehm T, Becker S, Becker-Pergola G, Sotlar K, Gebauer G, Durr-Storzer S, Neubauer H, Wall wiener D, and Solomayer EF: Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer. Breast Cancer Res 8: R60, 2006.
20. Pantel K, Muller V, Auer M, Nusser N, Harbeck N and Braun S: Detection and clinical implications of early systemic tumor cell dissemination in breast cancer. Clin Cancer Res 9: 6326-6334, 2003.
21. Braun S, Hepp F, Kentenich CR, Janni W, Pantel K, Riethmuller G, Willgeroth F and Sommer HL: Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. Clin Cancer Res 5: 3999-4004, 1999.
22. Hempel P, Muller P, Oruzio D, Behr W, Brockmeyer C, Wochner M, Ehnle S, Riethmuller R and Schlimok G: Combination of high-dose chemotherapy and monoclonal antibody in breast-cancer patients: a pilot trial to monitor treatment effects on disseminated tumor cells. Cytotherapy 2: 287-295, 2000.
23. Kirchner EM, Gerhards R and Voigtmann R: Sequential immunochemotherapy and edrecolomab in the adjuvant therapy of breast cancer: reduction of 17-1A-positive disseminated tumour cells. Ann Oncol 13: 1044-1048, 2002.
24. Bozionellou V, Mavroudis D, Perraki M, Papadopoulos S, Apostolaki S, Stathopoulos E, Stathopoulou A, Lianidou E and Georgoulias V: Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin Cancer Res 10: 8185-8194, 2004.
25. Saarto T, Vehmanen L, Virkkunen P and Blomqvist C: Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 43: 650-656, 2004.
26. Powles T, McCroskey E and Paterson A: Oral bisphosphonates as adjuvant therapy for operable breast cancer. Clin Cancer Res 72: 6301s-6304s, 2006.
27. Kokufu I, Kohno N, Takao M, Yamamoto M, Myashita S, Kohno S and Kimura F: Adjuvant Pamidronate (PMT) therapy for the prevention of bone metastasis in breast cancer (BC) patients (pts) with four or more positive nodes. Proc Am Soc Clin Oncol Abstr, 530, 2004.
28. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rucklinger E, Greil R and Marth C: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360: 679-691, 2009.
29. Diel IJ, Jaschke A, Solomayer EF, Gollan C, Bastert G, Sohn C and Schuetz F: Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 19: 2007-2011, 2008.
30. Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, Von Minckwitz G, Miller J, Schenk N and Coleman R: Efficacy of Zoledronic acid in postmeopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study. Ann Oncol, 2010.